EBA updates guidelines on disclosure of non-performing exposures and forbearance under CRR, amending EBA/GL/2018/10 to clarify scope for small, simple, and unlisted credit institutions, effective December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and renegotiated exposures, updating scope for small, non-complex, and non-listed credit institutions under CRR (Regulation (EU) No 575/2013), effective from December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure requirements for non-performing and forborne exposures – updating scope for small, non-complex, and other institutions under CRR (Regulation (EU) No 575/2013) with compliance reporting by January 2023.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and forborne exposures – updating scope and reporting requirements for credit institutions under CRR (Regulation (EU) No 575/2013), effective from December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and forborne exposures, targeting credit institutions and competent authorities under EU Regulation 575/2013, effective from December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure requirements for non-performing and restructured exposures, applying from December 2022 to credit institutions under CRR (EU) No 575/2013, including small, non-complex, and unlisted institutions.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and restructured exposures, updating scope for small, non-complex, and non-listed credit institutions under CRR (Regulation (EU) No 575/2013) – effective December 2022.
EBA updates guidelines on disclosure of non-performing and restructured exposures under Regulation (EU) 575/2013, clarifying scope for small, low-complexity, and unlisted credit institutions – effective December 2022 with compliance reporting by January 2023.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and forborne exposures, targeting credit institutions under CRR (Regulation (EU) No 575/2013), with compliance reporting required by January 2023 and application from December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing and restructured exposures, updating scope for listed small institutions and unlisted banks under CRR, effective December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing exposures and forbearance, updating scope for small non-complex and non-listed credit institutions under CRR (EU) No 575/2013, applicable from December 2022.
EBA guidelines amending EBA/GL/2018/10 on disclosure of non-performing exposures and forbearance measures, effective December 2022, targeting small non-complex and other non-listed credit institutions under CRR (Regulation (EU) No 575/2013).
European Banking Authority (EBA) guidelines amending EBA/GL/2018/10 on disclosure of non-performing and forborne exposures – updating requirements for small, non-complex, and other credit institutions under EU Regulation 575/2013, effective December 2022.
European Forum for Innovation Facilitators (EFIF) October 2022 meeting minutes – covering updates on innovation facilitators, crypto assets, NFTs, EU Digital Finance Platform progress, 2023 work programme priorities, and RegTech solutions for ESG and regulatory reporting.
Resolvability Testing Guidelines - background and key mesures
The European Banking Authority (EBA) today published its final Regulatory Technical Standards (RTS) on specific liquidity measurement for investment firms under the Investment Firms Directive (IFD). These RTS will ensure that all competent authorities follow the same harmonised approach when adopting the decision to impose further liquidity requirements to an investment firm.
Draft Regulatory Technical Standards on specific liquidity measurement for investment firms
EBA and ESMA joint Q&A update from November 2022 clarifying PRIIPs Key Information Document (KID) requirements, covering risk assessment, performance scenarios, cost calculations, and product-specific guidance for investment funds, derivatives, and insurance-based products.